The DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Alembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya to treat uUTIs.

A discussion on formulation development, contract services, and some of the critical considerations when moving from molecule to clinic.

The U.S. Food and Drug Administration’s (FDA’s) evolving guidance on Computer Software Assurance and AI/ML-Based Software ...

Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 ...

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some ...

The FDA has approved Takeda’s new immunoglobulin therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat ...

Scientific experts are concerned about what role vaccines will play in US public health strategy under the Trump ...

Torrent has signed definitive agreements to acquire stake in JB Pharma at an equity valuation of Rs256.89bn ($3bn) on a fully ...

As the pharma sector braces for sector-specific tariffs from President Trump, what could the impact look like on supply ...

Equipped with a new CEO, Vor Bio is transitioning into an autoimmune player, leaving cell and gene therapy behind.